Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Marburg virus glycoprotein (MARV GP) - Niemann-Pick C1 (NPC1) receptor binding site is a critical molecular junction required for the entry of Marburg virus into host cells. The viral GP is a trimeric surface protein that, upon internalization into host endosomes, undergoes proteolytic processing by host cathepsins to remove the glycan cap and mucin-like domain, thereby exposing the receptor binding site (RBS) on the GP1 subunit (Hashiguchi et al., 2015, Cell). This exposed RBS specifically binds to the luminal domain C of NPC1, a host intracellular cholesterol transporter that serves as an obligatory entry receptor for all known filoviruses (Carette et al., 2011, Nature; Ng et al., 2012, eLife). This binding event is the prerequisite for the subsequent conformational changes in the GP2 subunit that drive the fusion of viral and endosomal membranes. Because the GP-NPC1 interaction is a conserved and mandatory step in the viral life cycle, it represents a high-priority target for the development of antiviral therapies, such as monoclonal antibodies (e.g., MR191) and small-molecule inhibitors designed to block viral attachment and entry (King et al., 2018, Cell Reports). Targeting this site aims to block the viral entry process, thereby preventing the progression of Marburg virus disease, a severe and often fatal hemorrhagic fever.
The mechanism of action involves the competitive or steric inhibition of the binding between the primed (cathepsin-cleaved) Marburg virus glycoprotein 1 (GP1) subunit and the second luminal domain (Domain C) of the host Niemann-Pick C1 (NPC1) receptor. By preventing this interaction, the drug blocks the subsequent GP2-mediated membrane fusion, thereby halting the entry of the viral ribonucleoprotein into the host cell cytoplasm (Hashiguchi et al., 2015, Cell; Ng et al., 2012, eLife).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Marburg virus glycoprotein - Niemann-Pick C1 receptor binding site (MARV GP-NPC1 RBS).